Drug Company Abbott Picks Singapore for Trial of New Cancer Drug (Singapore)
This article was originally published in PharmAsia News
Executive Summary
Abbott has recently completed successful Phase I trials of a new cancer drug in Singapore. The company has also announced the selection of Singapore as home to the drug's Phase II trials. Abbott Regional Director Cihangir Kosu says the company chose Singapore because of its "solid infrastructure, high quality of healthcare services, and the existence of outstanding clinical research." The Phase II trials of the drug will occur over a period of six to 18 months. The drug's effectiveness will be tested on between 40 and 60 end-stage cancer patients, as opposed to the 21 tested in the Phase I trials. The new drug works by blocking blood-flow to cancer tumors. Subjects in the Phase I trials saw reductions in tumor size, while avoiding many of the serious side effects associated with most chemotherapy treatments. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.